Doubts over anti-obesity drugs

Anti-obesity drugs are unlikely to permanently reduce patients' weight, Canadian research findings suggest.

A meta-analysis showed little evidence that orlistat, sibutramine or rimonabant reduced patients' weight by 5 per cent as required by NICE. Such 'modest' weight loss could mean many patients will remain significantly overweight or obese despite drug treatment, say the researchers.

The study focused on 30 randomised placebo-controlled studies into anti-obesity drugs, involving almost 20,000 patients treated for at least one year.

Analysis showed that compared with placebo, orlistat reduced weight by an average of 2.9kg, sibutramine by 4.2kg and rimonabant by 4.7kg. Because the average starting weight of participants was 100kg, the drugs often failed to reduce significant body weight.

Between 30 and 40 per cent of participants dropped out of the trials, potentially affecting perceived effectiveness of the drug.

In 2006 NICE published public guidance on obesity. Use of orlistat and sibutramine was recommended in patients with a BMI of 30 or more who fail to respond to lifestyle interventions.

According to NICE, treatment should only be continued beyond six months if the patient manages to lose 5 per cent of their body weight in that time.

Dr David Haslam, clinical director of the National Obesity Forum and Hertfordshire GP, said that average weight loss was not a useful measure. This is because patients are responders or non-responders.

'Responders will lose a lot more,' said Dr Haslam, adding that this could be as much as 10-15 per cent in some patients.

If no response is seen at six months, GPs should 'try a different medication or reinforce lifestyle modifications', he said.

The research also found that the effect of weight loss drugs on comorbidities differed.

All three lowered cholesterol and orlistat was seen to reduce incidence of obesity. Sibutramine raised BP and pulse rate.

Anti-obesity drugs

  • Average weight loss less than 5 per cent body weight.
  • All three reduced cholesterol.
  • Orlistat reduced diabetes.
  • Sibutramine raised BP.
  • Rimonabant improved glycaemic control.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Close up of hand holding sample tube with 'Omicron' handwritten on side

Government urged to 'free up' GP practices and expand steps to control Omicron

GPs have called for immediate action such as suspension of QOF to allow practices...

(Photo: Mike Kemp/Getty Images)

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

External wall of GP surgery with wording 'medical centre'

‘Utterly toxic’: GPs speak out over abuse and physical attacks on practice teams

GPs have condemned a rise in verbal and physical attacks on practice staff - warning...

Artist's image of a spiked virus

Javid warns of 'substantial risk' from new COVID-19 variant

The highly mutated COVID-19 variant B.1.1.529 'may pose a significant risk to public...

Desk with lettering 'LMC conference'

LMCs reject 'outdated' GMS contract and demand move to item of service payments

LMCs have voted to scrap the 'outdated and inadequate' GMS contract and to replace...

GPs at an LMC conference waving green voting cards in the air

LMCs demand ringfence on enhanced services cash and clear GP representation in ICSs

LMCs have called for a ringfence on enhanced services funding, along with a guarantee...